Literature DB >> 2200538

Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in aggressive lymphomas.

J H van Krieken1, M Raffeld, S Raghoebier, E S Jaffe, G J van Ommen, P M Kluin.   

Abstract

Thirty-two extranodal lymphomas of the gastrointestinal (GI) tract underwent molecular genetic analysis by Southern blotting using probes for the immunoglobulin genes and the bcl-1, bcl-2, and c-myc loci, commonly involved in lymphomagenesis. No bcl-1 rearrangements were found. There was only one large-cell lymphoma with a bcl-2 rearrangement. A rearrangement of the c-myc gene was found in six of eight Burkittlike lymphomas of the intestine. In five of these six cases, a chromosomal translocation t(8;14) with an unusual breakpoint was demonstrated by comigration of the rearranged c-myc and a rearranged JH sequence. This pattern of rearrangement has not been previously associated with a specific group of non-Hodgkin's lymphomas. In contrast to all six low-grade lymphomas, c-myc rearrangements were found in 6 of 12 large-cell or high-grade mucosa-associated lymphomas of the stomach. No comigration of c-myc and immunoglobulin heavy-chain gene sequences were found. We conclude that primary GI lymphomas have different molecular genetic characteristics compared with node-based follicle center-cell lymphoma and as a group are not related to these lymphomas. In addition, the prevalence and patterns of c-myc rearrangements in the gastric large-cell lymphomas and ileocecal Burkittlike lymphomas are noteworthy and suggest a different and distinct pathogenesis for these tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200538

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis.

Authors:  Song-Yi Choi; Seok Jin Kim; Won Seog Kim; Kihyun Kim; Young-Hyeh Ko
Journal:  Virchows Arch       Date:  2011-10-15       Impact factor: 4.064

2.  Exclusive detection of the t(11;18)(q21;q21) in extranodal marginal zone B cell lymphomas (MZBL) of MALT type in contrast to other MZBL and extranodal large B cell lymphomas.

Authors:  A Rosenwald; G Ott; S Stilgenbauer; J Kalla; M Bredt; T Katzenberger; A Greiner; M M Ott; B Gawin; H Döhner; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

4.  [Extranodal diffuse large B-cell lymphoma--an organotypic disease?].

Authors:  G Ott; A Rosenwald
Journal:  Pathologe       Date:  2007-02       Impact factor: 1.011

5.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1.

Authors:  Vanessa J Craig; Sergio B Cogliatti; Jochen Imig; Christoph Renner; Stefan Neuenschwander; Hubert Rehrauer; Ralph Schlapbach; Stephan Dirnhofer; Alexander Tzankov; Anne Müller
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

6.  Molecular characterization of primary mediastinal B cell lymphoma.

Authors:  P Tsang; E Cesarman; A Chadburn; Y F Liu; D M Knowles
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

7.  Different bcl-2 protein expression in high-grade B-cell lymphomas derived from lymph node or mucosa-associated lymphoid tissue.

Authors:  R Villuendas; M A Piris; J L Orradre; M Mollejo; R Rodriguez; M Morente
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

Review 8.  Prognostic factors in the non-Hodgkin's lymphomas--a time for consensus?

Authors:  J A Child
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

Review 9.  New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-11-19       Impact factor: 0.196

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.